Swiss authorise remdesivir for wide use against coronavirus

SWITZERLAND announced on Thursday that COVID-19 patients beyond those on clinical trials could be given remdesivir, the first drug shown to be relatively effective in treating the new coronavirus.

At least two major US studies have shown that the anti-viral drug can reduce the duration of hospital stays for those suffering from the novel coronavirus.

“With immediate effect, remdesivir can be used more widely in Switzerland for the treatment of COVID-19 patients,” the government said in a statement.

Following a swift review this week, Swissmedic, the national agency for therapeutic products, said it would allow the temporary distribution of the drug, which was originally intended as a treatment for Ebola. “Products containing the active substance remdesivir and marketed under the brand name Veklury may be used in Swiss hospitals, without authorisation, for the treatment of COVID-19 patients,” the statement said.

The product will be made available to patients outside approved clinical trials and the approved compassionate use programme, pending a decision on full authorisation of the drug. Clinicians will monitor any adverse reactions to the drug to ensure patient safety, the government said.

Switzerland had largely got the virus under control, but, from a low and stable base, has witnessed a resurgence in cases in the last week or so.